HAL Allergy Group

HAL Allergy Group (HAL Allergy) is a modern leader and innovator in the field of biopharmaceuticals and located at the Bio Science Park in Leiden, The Netherlands. Our focus since 1959 stems from the development, production and distribution of Allergen Immunotherapies for the treatment and prevention of allergic diseases. These immunotherapies are used primarily against common allergies such as hay fever, house dust mite allergy and allergic reactions towards wasp or bee stings. With offices in major European countries, HAL Allergy is one of the European top players, particularly in the field of allergy. We take more than a little pride in our international leading role in the production of allergen extracts, both for therapeutic and diagnostic purposes. In addition, we have an specific expertise in the area of contract manufacturing with focus on the production of biopharmaceutical products for preclinical and clinical studies. HAL Allergy originally stems from 'Haarlems Allergenen Laboratorium', a Dutch company set up in Haarlem. The company started as a small laboratory where, on request of several local general practitioners (GPs), extracts were prepared on a named patient basis to treat against allergic reactions. The core business of HAL Allergy was, and still is, the treatment of allergies with specific immunotherapies. Patients' well-being is always our top priority. We employ around 300 highly specialized people across various functions. The departments at our headquarters include development, production, quality assurance and control, clinical and registration. Our staff works closely together with leading research institutes. At our locations in Germany, Poland, Austria, Spain and Italy we mainly focus on service and sales activities. HAL Allergy is a subsidiary of the family owned Droege Group International AG.